VIMIAN Stock Overview
Engages in the animal health business worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Vimian Group AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 44.00 |
| 52 Week High | SEK 47.20 |
| 52 Week Low | SEK 23.54 |
| Beta | 1.6 |
| 11 Month Change | -2.87% |
| 3 Month Change | 2.56% |
| 1 Year Change | 75.16% |
| 33 Year Change | -44.30% |
| 5 Year Change | n/a |
| Change since IPO | -45.61% |
Recent News & Updates
Recent updates
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%
Aug 31
Is Vimian Group (STO:VIMIAN) A Risky Investment?
Aug 17Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 18Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Apr 09Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Feb 13Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues
Jan 08Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching
Dec 03There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital
Nov 01Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price
Aug 27When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?
Jul 19Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?
May 19Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Apr 04Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Jan 06Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
Dec 09Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 38% Discount?
Aug 25We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)
Jun 18Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?
May 19Does This Valuation Of Vimian Group AB (publ) (STO:VIMIAN) Imply Investors Are Overpaying?
Feb 07Risks Still Elevated At These Prices As Vimian Group AB (publ) (STO:VIMIAN) Shares Dive 28%
Nov 30Shareholder Returns
| VIMIAN | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 4.0% | -2.6% | -0.2% |
| 1Y | 75.2% | -6.3% | 11.8% |
Return vs Industry: VIMIAN exceeded the Swedish Medical Equipment industry which returned -6.3% over the past year.
Return vs Market: VIMIAN exceeded the Swedish Market which returned 11.8% over the past year.
Price Volatility
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: VIMIAN has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: VIMIAN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1,100 | Patrik Eriksson | vimian.com |
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.
Vimian Group AB (publ) Fundamentals Summary
| VIMIAN fundamental statistics | |
|---|---|
| Market cap | SEK 23.02b |
| Earnings (TTM) | SEK 2.94m |
| Revenue (TTM) | SEK 4.05b |
7,820x
P/E Ratio5.7x
P/S RatioIs VIMIAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIMIAN income statement (TTM) | |
|---|---|
| Revenue | €352.39m |
| Cost of Revenue | €105.67m |
| Gross Profit | €246.72m |
| Other Expenses | €246.46m |
| Earnings | €256.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 0.00049 |
| Gross Margin | 70.01% |
| Net Profit Margin | 0.073% |
| Debt/Equity Ratio | 35.9% |
How did VIMIAN perform over the long term?
See historical performance and comparison